Key result
High-dose chemotherapy followed by hematopoietic stem cell transplantation significantly impaired endothelial function in patients with hematologic malignancies, reducing flow-mediated dilatation from 10.14% to 6.43% (p<0.001).
Why the study?
Does high-dose chemotherapy followed by HSCT impair endothelial function in patients with hematologic malignancies?
Observational (n=38)
No
Does high-dose chemotherapy followed by HSCT impair endothelial function in patients with hematologic malignancies?
High-dose chemotherapy and HSCT significantly impair endothelial function, with fludarabine, cytarabine, and elevated creatinine identified as specific risk factors for this vascular toxicity.
HSCT-associated endothelial impairment may signal elevated CV risk; leaves open whether risk-factor mitigation improves outcomes.
The aim of the study was to examine endothelial function in patients with hematological malignancies treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation. The studies were conducted on 43 consecutive patients qualified for HSCT following high-dose chemotherapy based on the current standards. Then, due to exclusion criteria, a group of 38 patients were chosen for further investigations. Evaluation of endothelial function by means of flow-mediated dilatation (FMD) was conducted in patients with hematological malignancies before HSCT (test A) and after HSCT (test B). Brachial artery diameter (BAD) after occlusion, change in BAD and FMD were significantly lower after HSCT as compared to the results obtained before the transplantation (p < 0.05). The regression analysis indicated that administration of fludarabine and cytarabine, and also higher blood concentrations of creatinine represented risk factors for the impairment of endothelial function expressed as decreased FMD value. In patients with hematopoietic malignancies treated with HSCT, endothelial function assessed by the flow-mediated dilatation was impaired after chemotherapy and stem cell administration.
No takes yet. Share an insight, caveat, or question.
Poręba et al. (2015) conducted an observational in Hematologic malignancies (n=38). High-dose chemotherapy and hematopoietic stem cell transplantation vs. Baseline (before procedure) was evaluated on Flow-mediated dilatation (FMD) (p=<0.001). High-dose chemotherapy followed by hematopoietic stem cell transplantation significantly impaired endothelial function in patients with hematologic malignancies, reducing flow-mediated dilatation from 10.14% to 6.43% (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: